Suppr超能文献

通过基因枪将CIITA DNA与DNA疫苗共同给药来增强DNA疫苗效力。

Enhancement of DNA vaccine potency through coadministration of CIITA DNA with DNA vaccines via gene gun.

作者信息

Kim Daejin, Hoory Talia, Monie Archana, Ting Jenny Pan-Yun, Hung Chien-Fu, Wu T-C

机构信息

Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA.

出版信息

J Immunol. 2008 May 15;180(10):7019-27. doi: 10.4049/jimmunol.180.10.7019.

Abstract

Administration of DNA vaccines via gene gun has emerged as an important form of Ag-specific immunotherapy. The MHC CIITA is a master regulator of MHC class II expression and also induces expression of class I molecules. We reasoned that the gene gun administration of CIITA DNA with DNA vaccines employing different strategies to improve MHC I and II processing could enhance DNA vaccine potency. We observed that DC-1 cells transfected with CIITA DNA lead to higher expression of MHC I and II molecules, leading to enhanced Ag presentation through the MHC I/II pathways. Furthermore, our data suggested that coadministration of DNA-encoding calreticulin (CRT) linked to human papillomavirus (HPV) 16 E6 Ag (CRT/E6) with CIITA DNA leads to enhanced E6-specific CD8(+) T cell immune responses in vaccinated mice. In addition, coadministration of the combination of CRT/E6 DNA with CIITA DNA and DNA encoding the invariant chain (Ii) linked to the pan HLA-DR-reactive epitope (Ii-PADRE) further enhanced E6-specific CD8(+) T cell immune responses in vaccinated mice. Treatment with the combination vaccine was also shown to enhance the antitumor effects and to prolong survival in TC-1 tumor-bearing mice. Vaccination with the combination vaccine also led to enhanced E6-specific CD8(+) memory T cells and to long-term protection against TC-1 tumors and prolonged survival in vaccinated mice. Thus, our findings suggest that the combination of CIITA DNA with CRT/E6 and Ii-PADRE DNA vaccines represents a potentially effective means to combat tumors in the clinical setting.

摘要

通过基因枪接种DNA疫苗已成为一种重要的抗原特异性免疫疗法。MHC CIITA是MHC II类表达的主要调节因子,也能诱导I类分子的表达。我们推测,用基因枪接种CIITA DNA与采用不同策略改善MHC I和II加工的DNA疫苗相结合,可能会增强DNA疫苗的效力。我们观察到,用CIITA DNA转染的DC-1细胞导致MHC I和II分子的表达更高,从而通过MHC I/II途径增强抗原呈递。此外,我们的数据表明,将与人类乳头瘤病毒(HPV)16 E6抗原(CRT/E6)相连的编码钙网蛋白(CRT)的DNA与CIITA DNA共同接种,可增强接种疫苗小鼠中E6特异性CD8(+) T细胞免疫反应。此外,将CRT/E6 DNA与CIITA DNA以及与泛HLA-DR反应性表位(Ii-PADRE)相连的编码恒定链(Ii)的DNA联合接种,进一步增强了接种疫苗小鼠中E6特异性CD8(+) T细胞免疫反应。联合疫苗治疗还显示可增强抗肿瘤作用,并延长携带TC-1肿瘤小鼠的生存期。接种联合疫苗还导致E6特异性CD8(+) 记忆T细胞增加,并对TC-1肿瘤提供长期保护,延长接种疫苗小鼠的生存期。因此,我们的研究结果表明,CIITA DNA与CRT/E6和Ii-PADRE DNA疫苗联合使用是临床上对抗肿瘤的一种潜在有效手段。

相似文献

1
Enhancement of DNA vaccine potency through coadministration of CIITA DNA with DNA vaccines via gene gun.
J Immunol. 2008 May 15;180(10):7019-27. doi: 10.4049/jimmunol.180.10.7019.
2
Innovative DNA vaccine for human papillomavirus (HPV)-associated head and neck cancer.
Gene Ther. 2011 Mar;18(3):304-12. doi: 10.1038/gt.2010.151. Epub 2010 Oct 28.
6
Pretreatment with cisplatin enhances E7-specific CD8+ T-Cell-mediated antitumor immunity induced by DNA vaccination.
Clin Cancer Res. 2008 May 15;14(10):3185-92. doi: 10.1158/1078-0432.CCR-08-0037.
7
Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6.
J Virol. 2004 Aug;78(16):8468-76. doi: 10.1128/JVI.78.16.8468-8476.2004.
8
Comparison of HPV DNA vaccines employing intracellular targeting strategies.
Gene Ther. 2004 Jun;11(12):1011-8. doi: 10.1038/sj.gt.3302252.

引用本文的文献

1
Therapeutic DNA Vaccines for Human Papillomavirus and Associated Diseases.
Hum Gene Ther. 2018 Sep;29(9):971-996. doi: 10.1089/hum.2017.197. Epub 2018 Mar 16.
3
Polymeric Materials for Gene Delivery and DNA Vaccination.
Adv Mater. 2009 Feb 23;21(8):847-867. doi: 10.1002/adma.200801478. Epub 2008 Dec 4.
4
The rationale of vectored gene-fusion vaccines against cancer: evolving strategies and latest evidence.
Ther Adv Vaccines. 2013 May;1(1):33-47. doi: 10.1177/2051013613480446.
5
Cross-protection against drifted influenza viruses: options offered by adjuvanted and intradermal vaccines.
Hum Vaccin Immunother. 2013 Mar;9(3):582-90. doi: 10.4161/hv.23239. Epub 2013 Jan 7.
6
Targeted treatments for cervical cancer: a review.
Onco Targets Ther. 2012;5:315-28. doi: 10.2147/OTT.S25123. Epub 2012 Nov 2.
7
The future of human DNA vaccines.
J Biotechnol. 2012 Dec 31;162(2-3):171-82. doi: 10.1016/j.jbiotec.2012.08.012. Epub 2012 Sep 7.
8
Induction of robust cellular immunity against HPV6 and HPV11 in mice by DNA vaccine encoding for E6/E7 antigen.
Hum Vaccin Immunother. 2012 Apr;8(4):470-8. doi: 10.4161/hv.19180. Epub 2012 Feb 16.
9
Advances in Gene Delivery Systems.
Pharmaceut Med. 2011 Oct 1;25(5):293-306. doi: 10.2165/11594020-000000000-00000.
10
TAA polyepitope DNA-based vaccines: a potential tool for cancer therapy.
J Biomed Biotechnol. 2010;2010:102758. doi: 10.1155/2010/102758. Epub 2010 Jun 17.

本文引用的文献

2
The absence of invariant chain in MHC II cancer vaccines enhances the activation of tumor-reactive type 1 CD4+ T lymphocytes.
Cancer Immunol Immunother. 2008 Mar;57(3):389-98. doi: 10.1007/s00262-007-0381-5. Epub 2007 Aug 28.
3
Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells.
Expert Rev Vaccines. 2007 Apr;6(2):227-39. doi: 10.1586/14760584.6.2.227.
5
Modifying professional antigen-presenting cells to enhance DNA vaccine potency.
Methods Mol Med. 2006;127:199-220. doi: 10.1385/1-59745-168-1:199.
6
Cooperation between CD4+ and CD8+ T cells: when, where, and how.
Annu Rev Immunol. 2006;24:519-40. doi: 10.1146/annurev.immunol.23.021704.115825.
8
Regulation of MHC class II gene expression by the class II transactivator.
Nat Rev Immunol. 2005 Oct;5(10):793-806. doi: 10.1038/nri1708.
9
Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6.
J Virol. 2004 Aug;78(16):8468-76. doi: 10.1128/JVI.78.16.8468-8476.2004.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验